A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV

Abstract

In stably suppressed patients, 200 mg emtricitabine QD was equivalent to 150 mg lamivudine BID. Emtricitabine-containing HAART was associated with a high rate of sustained virologic suppression during 4 years of follow-up.

Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients

“…Immunological testing indicated an increased CD4 cell count in both naïve and experienced patients (mean change: 50-200 cells/mm 3 ). These findings are similar to the results of previous reports [11][12][13], and this study provides evidence that cART containing FTC and TDF is effective in controlling symptoms both virologically and immunologically in Japanese patients infected with HIV-1.…”

A Comparison of the Phenotypic Susceptibility Profiles of Emtricitabine and Lamivudine

“…Given the greater activity and longer intracellular half-life of FTC compared with 3TC, these small differences in FC are unlikely to be clinically significant. In a clinical study of FTC versus 3TC in treatment-experienced patients (Benson et al, 2004), no differences were observed in the number of patients experiencing virological failure between the two arms; only the M184V mutation was significantly associated with virological failure in this study (Van der Horst C, Quinn JB, Hinkle J, Bae A, Borroto-Esoda K, Moxham C, Rousseau F. Predictors of virologic failure in HIV-1 infected adults on a stable lamivudine HAART regimen. 42nd Annual Interscience Conference on Antimicrobial Agents andChemotherapy.…”

New Antiretroviral Therapies for Pediatric HIV Infection

“…7 In adult patients, FTC demonstrated significantly greater viral suppression than 3TC in a short-term monotherapy study and displayed antiviral equivalence to 3TC when administered as part of a combination antiretroviral regimen. 8,9 Virologic response to FTC was superior to stavudine (d4T) when either agent was administered in combination with efavirenz (EFV) and enteric-coated didanosine (ddI EC). 10 The efficacy of a once-daily regimen including FTC, ddI EC, and EFV was confirmed in adults both in a pilot study and a randomized, open-label trial.…”

“…3 In comparator trials, reports of adverse reactions were similar between FTC and 3TC but were less common with FTC compared to d4T. [8][9][10] In adults, grade 3 and 4 laboratory abnormalities were also similar to those of 3TC and d4T during combination therapy. 6,7,14 Most common (occurring in > 5% of patients) were increased creatinine kinase, triglycerides, hepatic transaminases, and serum amylase, and decreased neutrophil counts.…”